From the Guidelines
The recommended dose of Ipratropium bromide inhaler for adults with COPD or asthma is 2-8 puffs every 20 minutes as needed up to 3 hours, with each puff containing 18 mcg of ipratropium bromide. This dose is based on the guidelines provided by the expert panel report 3 (epr-3): guidelines for the diagnosis and management of asthma-summary report 2007 1. The medication works as an anticholinergic bronchodilator, helping to relax the smooth muscles in the airways and improve airflow. Some key points to consider when using ipratropium bromide inhaler include:
- Shaking the inhaler well before use
- Exhaling fully before inhaling the medication slowly and deeply
- Holding breath for 10 seconds if possible after inhalation
- Rinsing mouth after use to prevent dry mouth and throat irritation
- Not exceeding the maximum daily dose, which is not explicitly stated in the provided evidence but should be guided by the principle of using the minimum effective dose to control symptoms. It's also important to note that ipratropium bromide can be used in combination with other medications, such as albuterol, for the management of severe exacerbations 1.
From the FDA Drug Label
The usual dosage of ipratropium bromide inhalation solution is 500 mcg (1 Unit-Dose Vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. The recommended dose of Ipratropium (ipratropium bromide) inhaler for adults with Chronic Obstructive Pulmonary Disease (COPD) or asthma is 500 mcg administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart 2.
From the Research
Ipratropium Inhaler Dose for Adults with COPD or Asthma
The recommended dose of Ipratropium (ipratropium bromide) inhaler for adults with Chronic Obstructive Pulmonary Disease (COPD) or asthma is not explicitly stated in the provided studies. However, the following information can be gathered:
- Ipratropium bromide is an anticholinergic bronchodilator administered by inhalation, which produces bronchodilation in most patients with obstructive airways disease 3.
- The usual inhaled doses of ipratropium were well tolerated in all studies, but the exact dose is not specified 3.
- Ipratropium may be used as an adjunctive therapy for the emergency treatment of acute asthma exacerbation, and the addition of inhaled ipratropium to inhaled beta2-agonist therapy has been shown to be effective in improving lung function and reducing hospitalization rates 4.
- The use of ipratropium in combination with other bronchodilating drugs, such as beta2-agonists, may be beneficial for patients with COPD or asthma who do not respond adequately to a single drug regimen 3, 4.
Key Points to Consider
- Ipratropium bromide is a quaternary anticholinergic bronchodilator that is commonly used to treat obstructive lung disease 4.
- The choice of agents for COPD management is based primarily on disease stage, individual response, cost, side effect profile, and availability 5.
- Combination therapy with an inhaled corticosteroid and a long-acting beta2-agonist (ICS/LABA) is an effective therapy for COPD, but the role of ipratropium in this combination is not clearly defined in the provided studies 6, 7.
- Ipratropium may be useful in patients with COPD or asthma who experience side effects with beta2-agonists, such as palpitations or tremor 3.